Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-20-058237
Date:2020-11-11
Issuer: FIVE PRIME THERAPEUTICS, INC. (FPRX)
Original Submission Date:

Reporting Person:

COLLINS HELEN LOUISE
111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-11-11 M 22,000 a $0.00 86,156 direct
COMMON STOCK 2020-11-11 F 11,039 d $18.00 75,117 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
PERFORMANCE-BASED RESTRICTED COMMON STOCK 0.0 2020-11-11 deemed execution date M 22,000 (d) common stock 22,000 $0.00 22,000 direct
Footnotes
IDfootnote
f1 represents shares of performance-based restricted common stock granted to the reporting person on june 24, 2019. these shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of five prime therapeutics, inc. (the "company") was greater than or equal to $12.95.
f2 the shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this report.
f3 represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the company was greater than or equal to $12.95.
f4 the remaining shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the company is greater than or equal to $19.43, subject to the reporting person's continued service to the company through such date; provided that such shares shall automatically expire and be forfeited if such shares have not vested by december 31, 2021.
WhaleWisdom Logo

Elevate your investments